Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TMBR....................................https://stockcharts.com/h-sc/ui?s=TMBR&p=W&b=5&g=0&id=p86431144783
Offering was actually changed to .12c
https://finance.yahoo.com/news/timber-pharmaceuticals-announces-closing-8-200500650.html
$TMBR
$TMBR
.21 cent offering dropped to .12 cents recently
volume 47 million picking up.
Breakout coming
$TMBR Bottom channel reversal. Price retest on 100sma. Increasing technicals. Increasing OBV. Increasing momentum. RSI 57. 14 day ADX Inclining @ 35
OK the RS proposal failed miserably - now TMBR management needs to get to work to move this thing forward based on results not a RS.
Get busy, you all are paid really well for what we shareholders get for it.
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
May 31 2022 - 08:00AM
– Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, for the treatment of congenital ichthyosis (CI).
“This is a significant moment for people who are living with CI, their families and caregivers, and clinicians and researchers who have been working for years to find new treatment options for this debilitating condition,” said John Koconis, Chairman and Chief Executive Officer of Timber. “A Breakthrough Therapy designation is no small achievement. Through half of FDA’s 2022 fiscal year, more breakthrough applications have been rejected by FDA or withdrawn (16), than have been granted (9). I am proud of our team for demonstrating the potential of TMB-001 in our Phase 2b program, and we are rapidly pushing forward with a pivotal Phase 3 clinical trial.”
Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat serious or life-threatening conditions. Preliminary clinical evidence must indicate that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
Timber is developing TMB-001 for the treatment of moderate to severe forms of CI, including X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI). CI is a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. In patients with XRI and ARCI-LI, cutaneous manifestations include large, dark scaling throughout the body.
In the Phase 2b CONTROL study, treatment with TMB-001 demonstrated a clinically meaningful reduction in targeted and overall severity of CI along with a favorable safety profile. A sub-analysis of the study presented at the American Academy of Dermatology (AAD) 2022 Annual Meeting showed patients achieved treatment success with TMB-001 regardless of the subtype of CI.
Timber has initiated the pivotal Phase 3 ASCEND clinical trial to further investigate the efficacy and safety of TMB-001 for the treatment of CI at leading research centers in the U.S., Canada, Italy, France, and Germany and is expecting to dose the first patients in June 2022. The ASCEND trial will evaluate the efficacy, pharmacokinetics and safety of TMB-001 0.05% in 142 patients with moderate to severe CI.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and other sclerotic skin diseases. For more information, visit www.timberpharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
$TMBR News Out: Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
https://www.timberpharma.com/news-releases
A Fast Track designation allows for more frequent meetings and written communication from the FDA to discuss a drug's development plan and the design of proposed clinical trials to ensure collection of appropriate data needed to support drug approval. Fast Track designation also allows FDA to conduct a rolling review of an NDA or BLA, which means that a drug company can submit completed sections of its application to FDA for review, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. A drug that receives Fast Track designation may also be eligible for Accelerated Approval and Priority Review.
Why ? TMBR looks like a pretty good buying op here today.
You can't flip trials lmao, go back to the memes
TMBR Statistics Data
Shares Outstanding
73.60M
Float
60.44M
Insider Ownership
0.10%
Insitutional Ownership
4.30%
First Biotech holiday runner let go Timbbbeeerrr
CC on Monday lets rise into it...
https://finance.yahoo.com/news/timber-pharmaceuticals-host-conference-call-211800318.html
I dipped a couple of toes into the water here, it should reach at least .70 so they can convert the warrants before it heads back over $1 - My target is $1.26 or better based solely on the offering price
Thanks for your input, Ernie
I used to follow them awhile back when they were well over $1, doing some new DD and I can't seem to find if their exchange requires them to remain above $1. A buddy of mine uses a different broker and his doesn't have the warning on the ticker LOL go figure
RSI oversold so there is upside, but sentiment seems to be really bad at this point......as it should be after another offering IMO
I'm still going to keep a close eye on it
I don't think RS will be necessary, but I haven't followed them for longer than a week so who knows?
Will $TMBR need to R/S to get back above $1? My broker has the warning up on this ticker
Jeeeez just saw news of offering closed, that crushed the share price
$TMBR always has been the king of dilution. Wow
No one has confidence in the company right now. And now we are getting into tax loss harvesting time. They really need to issue some positive news--if they have any--to make it a more difficult decision for holders on whether to sell TMBR or another lower in their portfolio to get the tax loss.
The dilution necessary to bring in capital keeps them alive, but the under market pricing of the offering did not help.
JMO
Gm what’s the story here?
What was the amount of the offering ?
TIMBER.......sorry...I had too.....
Fell asleep.......Offering.....Wait for fifties.....
And now the POS just put the last nail in their coffin.
Terrible chart
Needs a high volume bottom reversal to bring in more investors.
TMBR...96...Bullish 3 Gap Downs Reversal Pattern to the Upside formed on this Oversold Chart...Been adding the dip...
Accumulation and Money Flow suggest a strong Upside move is setting up here...imo...we shall see...
Chart...https://schrts.co/ahCmkPAw ...
Trying to keep a lid on this one at below $1.29/share. Waiting for stock to bust out./ok2
Agreed. Look at the chart, wasn't that long ago that we were trading above $2.00/share. Retailers will take this higher./ok2
this little stock is showing signs of waking up
Once we rechallenge the $1.50's, this stock could easily move back up to the $2.00 range./ok2
News out after trading today. Company has favourable Phase 2a/b results for candidate TMB-001. Approaching the FDA to accelerate to Phase 3 trials to fill unmet need in ichthyosis. This one could run hard tomorrow and could approach $3/share in the short to mid term. Best of luck to the longs./ok2buy
Morningstar has a fair value for TMBR @ $1.51/share as of May 19/21. Trading below that. Won't last long. Oversold! Best of luck to the longs./ok2
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
188
|
Created
|
06/03/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |